Cyclarity Therapeutics Reports Safety Data for 7-Ketocholesterol Clearance (opens in new tab)

Cyclarity Therapeutics has been processing safety data from a phase 1 safety trial of a cyclodextrin drug to bind 7-ketocholesterol, a toxic form of oxidized cholesterol that contributes to a range of conditions. The company is initially focused on atherosclerosis, the formation of fatty plaques that obstruct blood vessels and ultimately rupture to cause a stroke or heart attack. It is thought that 7-ketocholesterol may be a significant factor in the toxic environment of atherosclerotic plaqu...